首页> 外文期刊>Annals of nuclear medicine >Diagnostic performance of planar scintigraphy using 99mTc-MIBI in patients with secondary hyperparathyroidism: A meta-analysis
【24h】

Diagnostic performance of planar scintigraphy using 99mTc-MIBI in patients with secondary hyperparathyroidism: A meta-analysis

机译:99mTc-MIBI平面闪烁显像对继发性甲状旁腺功能亢进症的诊断性能:荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Parathyroid scintigraphy using 99mTc-MIBI is not currently considered a valuable diagnostic tool for the localization of involved glands in patients with secondary hyperparathyroidism (SHPT). However, published data about its diagnostic accuracy are discordant and a meta-analysis about this topic is still lacking. The aim of our study is to meta-analyze the published data about the diagnostic performance of 99mTc-MIBI parathyroid scintigraphy in patients with SHPT. Methods: A comprehensive computer literature search of studies published in PubMed/MEDLINE, Scopus and Embase databases through September 2011 and regarding the diagnostic accuracy of 99mTc-MIBI parathyroid scintigraphy in patients with SHPT was carried out. Only articles in English language in which at least 10 patients with SHPT underwent planar 99mTc-MIBI parathyroid scintigraphy were selected. Pooled sensitivity, pooled specificity and area under the ROC curve on a per lesion-based analysis were calculated to measure the diagnostic accuracy of 99mTc-MIBI parathyroid scintigraphy in SHPT patients. Results: Twenty-four studies comprising 471 patients were included in this meta-analysis. The pooled sensitivity and specificity of 99mTc-MIBI parathyroid scintigraphy in detecting hyperplastic glands in SHPT patients were 58 % [95 % confidence interval (95 % CI) 52-65 %] and 93 % (95 % CI 85-100 %), respectively, on a per lesion-based analysis. Area under ROC curve was 0.75. Conclusions: In patients with SHPT and diffuse or nodular hyperplasia, planar parathyroid scintigraphy using 99mTc-MIBI has demonstrated an inadequate diagnostic accuracy. Therefore, it should not be considered as a first-line diagnostic imaging method in the pre-surgical detection of hyperplastic parathyroid glands. ? 2012 The Japanese Society of Nuclear Medicine.
机译:目的:目前尚不认为使用99mTc-MIBI进行甲状旁腺闪烁显像对继发性甲状旁腺功能亢进症(SHPT)患者的受累腺定位是一种有价值的诊断工具。但是,有关其诊断准确性的已发布数据不一致,并且仍缺乏对该主题的荟萃分析。我们研究的目的是对关于99mTc-MIBI甲状旁腺闪烁显像对SHPT患者的诊断性能的已发表数据进行荟萃分析。方法:对截至2011年9月发表在PubMed / MEDLINE,Scopus和Embase数据库中的研究以及99mTc-MIBI甲状旁腺闪烁显像对SHPT患者的诊断准确性进行了全面的计算机文献检索。仅选择至少10例SHPT患者行平面99mTc-MIBI甲状旁腺闪烁显像的英语文章。在基于病灶的分析中,计算合并的敏感性,合并的特异性和ROC曲线下的面积,以测量99mTc-MIBI甲状旁腺闪烁显像对SHPT患者的诊断准确性。结果:该荟萃分析包括二十四项研究,包括471位患者。 99mTc-MIBI甲状旁腺闪烁显像对SHPT患者增生腺的检测敏感性和特异性分别为58%[95%置信区间(95%CI)52-65%]和93%(95%CI 85-100%) ,基于病灶的分析。 ROC曲线下的面积为0.75。结论:对于SHPT并有弥漫性或结节性增生的患者,使用99mTc-MIBI进行的平面甲状旁腺闪烁显像显示诊断准确性不足。因此,在增生性甲状旁腺的术前检测中,不应将其视为一线诊断成像方法。 ? 2012年日本核医学学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号